Humacyte Plans 25M Share Common Stock Offering
Deal News | Mar 27, 2025 | Paul Hastings
Paul Hastings LLP is advising on the underwriting process for Humacyte, Inc.'s issuance of 25,000,000 shares of common stock. TD Cowen, Barclays and BTIG are serving as joint book-running managers, while H.C. Wainwright & Co. and The Benchmark Company are acting as lead managers. This significant equity offering is anticipated to close on or about March 27, 2025, contingent on customary closing conditions. The transaction is led by Paul Hastings' Co-head of Equity Capital Markets Seo Salimi, co-chair of the Corporate Life Sciences Group, and partner Will Magioncalda, supported by associates Chris Guerin and Adam Swank.
Sectors
- Legal Services
- Biotechnology
- Financial Services
Geography
- United States – Humacyte, Inc., the target company, is based in the United States, and the involved participants are primarily U.S.-based entities.
Industry
- Legal Services – Paul Hastings LLP is providing legal advisory services for the underwriting process.
- Biotechnology – Humacyte, Inc. is a biotechnology company conducting a significant equity offering.
- Financial Services – The transaction involves major financial entities, including TD Cowen, Barclays, BTIG, H.C. Wainwright & Co., and The Benchmark Company, as underwriters and managers.
Financials
- 25,000,000 shares – The number of shares of common stock offered by Humacyte, Inc.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Paul Hastings LLP | Legal Advisor | Company | An international law firm providing legal advisory services to the underwriters in Humacyte's common stock offering. |
| Humacyte, Inc. | Target Company | Company | A biotechnology company expected to offer 25,000,000 shares of common stock. |
| TD Cowen | Joint Book-Running Manager | Company | A financial services firm acting as a joint book-running manager in the transaction. |
| Barclays | Joint Book-Running Manager | Company | A major global financial services provider acting as a joint book-running manager. |
| BTIG | Joint Book-Running Manager | Company | A global financial services firm involved as a joint book-running manager. |
| H.C. Wainwright & Co. | Lead Manager | Company | A financial investment bank serving as a lead manager for the offering. |
| The Benchmark Company | Lead Manager | Company | An investment banking firm acting as a lead manager. |
| Seo Salimi | Co-head of Equity Capital Markets and Co-chair of Corporate Life Sciences Group | Person | Leading the Paul Hastings LLP team advising on the transaction. |
| Will Magioncalda | Partner | Person | Partner at Paul Hastings LLP, involved in overseeing the transaction. |
| Chris Guerin | Associate | Person | Associate at Paul Hastings LLP involved in the transaction. |
| Adam Swank | Associate | Person | Associate at Paul Hastings LLP involved in the transaction. |